← Leaderboards
Brunhilde Felding-Habermann
Scripps Research Institute
$9,161,380
Attributed
$12,059,733
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,330,683 · 12
By mechanism
R01$11,322,361 · 5
S10$541,900 · 4
R21$456,642 · 1
P41$6,224 · 1
M01$3,556 · 1
Top collaborators
- Dale L Boger5 shared
- Brian Patrick Eliceiri5 shared
- Vaughn Vasil Smider2 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- David A Case$15,745,856
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMolecularMalignant Breast NeoplasmMalignant NeoplasmsBreast Cancer CellBaseNeoplastic CellResistanceCancer PatientPreventGrowthCancer TherapyWomanCessation Of LifeTumor MicroenvironmentNovel TherapeuticsAffectLesionOperative Surgical ProceduresPenetrationResponseLeadEventClinic
Grant awards (35)
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2021 · CA
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2020 · CA
A Unique Class of Reductively Activated Oncology Drugs$697,415
R01 · FY2019 · CA
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2018 · CA
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2017 · CA
Vascular mechanisms regulating breast cancer brain metastasis$357,419
R01 · FY2016 · CA
Antibody Fingerprinting of Triple Negative Breast Cancer by High Throughput FACS$209,344
R21 · FY2016 · CA · contact PI
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$467,930
R01 · FY2015 · CA · contact PI
Vascular mechanisms regulating breast cancer brain metastasis$357,419
R01 · FY2015 · CA
Antibody Fingerprinting of Triple Negative Breast Cancer by High Throughput FACS$247,298
R21 · FY2015 · CA · contact PI
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$116,402
R01 · FY2015 · CA · contact PI
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$426,659
R01 · FY2014 · CA · contact PI
Vascular mechanisms regulating breast cancer brain metastasis$346,696
R01 · FY2014 · CA
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$112,910
R01 · FY2014 · CA · contact PI
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$439,854
R01 · FY2013 · CA · contact PI
Vascular mechanisms regulating breast cancer brain metastasis$335,974
R01 · FY2013 · CA
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$116,402
R01 · FY2013 · CA · contact PI
Normalizing Breast Cancer Metabolism to Prevent Progression and Recurrence (PQ21)$467,930
R01 · FY2012 · CA · contact PI
Vascular mechanisms regulating breast cancer brain metastasis$369,198
R01 · FY2012 · CA
Targeting Metastatic Breast Cancer with Human Antibodies$354,869
R01 · FY2009 · CA · contact PI
Targeting Metastatic Breast Cancer with Human Antibodies$354,869
R01 · FY2008 · CA · contact PI
Targeting Metastatic Breast Cancer with Human Antibodies$348,127
R01 · FY2007 · CA · contact PI
ADAPTATION OF ENERGY METABOLISM IN BREAST CANCER BRAIN METASTASES$6,224
P41 · FY2007 · RR · contact PI
Integrin Activation in Breast Cancer Metastasis$402,386
R01 · FY2006 · CA · contact PI
Targeting Metastatic Breast Cancer with Human Antibodies$358,525
R01 · FY2006 · CA · contact PI
Integrin Activation in Breast Cancer Metastasis$412,070
R01 · FY2005 · CA
Targeting Metastatic Breast Cancer with Human Antibodies$367,153
R01 · FY2005 · CA
IVIS 200 Imaging System$270,950
S10 · FY2005 · RR
IVIS 200 IMAGING SYSTEM: CANCER$216,759
S10 · FY2005 · RR
IVIS 200 IMAGING SYSTEM: BIOCHEMISTRY$40,643
S10 · FY2005 · RR
IVIS 200 IMAGING SYSTEM: CARDIOVASCULAR$13,548
S10 · FY2005 · RR
Integrin Activation in Breast Cancer Metastasis$412,070
R01 · FY2004 · CA
Integrin activation in breast cancer metastasis$3,556
M01 · FY2004 · RR
Integrin Activation in Breast Cancer Metastasis$412,070
R01 · FY2003 · CA
Integrin Activation in Breast Cancer Metastasis$412,070
R01 · FY2002 · CA